Does fisetin slow aging?

What we found

• Only one on-topic paper reports people taking fisetin: a small subgroup in a blood-marker study. The abstract gives no group size, dose or numbers. Hambright 2024
• In mice with obesity, lupus, kidney damage or muscular dystrophy, fisetin lowered worn-out cells and improved sugar handling, behavior, kidney repair or muscle. Suda 2025, Saito 2021, Li 2023, Liu 2022
• In 18-month-old mice, senolytic drugs including fisetin lowered one immune cell type in the heart; the abstract gives no fisetin-only result. Rodriguez Morales 2025
• A review of 13 cell and animal studies found fisetin helped against bone loss, with fewer reports on joint wear. It included no studies in people. Yamaura 2022

What the research says

What reviews of many studies found

Reviews pool or sum up earlier studies. They are not on the ladder, because they repeat studies already counted there.

• Systematic review · Yamaura 2022

  Checked 13 cell and animal studies of fisetin on bone and cartilage; they were too different to pool. Found benefit for bone loss and fewer, limited reports on joint wear. It included no studies in people.

• Systematic review · Gruendler 2020

  Reviewed three food-derived substances, including fisetin, on Alzheimer's disease hallmarks: cell clean-up, brain inflammation and worn-out cells. Reported a positive outlook. The abstract gives no study count and no fisetin-only results.

• Opinion or narrative review · Rzeski 2026

  Narrative review of four food compounds, including fisetin. Says fisetin clears worn-out cells and has emerging clinical evidence. It does not pool studies or give fisetin trial results.

How the research grew

The papers we read span 2020 to 2026. 5 of the 12 on-topic papers came out in 2024 to 2026.

1. 2020
   Reviews
2. 2021
   Animal and cellOpinion
3. 2022
   Animal and cellReviews
4. 2023
   Animal and cell
5. 2024
   Population studies
6. 2025
   Animal and cell
7. 2026
   Opinion

Each dot is one on-topic paper, colored by what it found. Rings mark key papers:

1. 2021. Fisetin by mouth cut worn-out brain cells in mice. Saito 2021
2. 2022. First systematic review of fisetin on bone and cartilage. Yamaura 2022
3. 2024. Only human data here: fewer worn-out blood cells. Hambright 2024
4. 2025. Senolytics including fisetin tested in naturally old hearts. Rodriguez Morales 2025
5. 2025. Fisetin cut worn-out vessel cells in obese mice. Suda 2025

Who funds this research

No fisetin trial in people is in this set, so no trial paper has a stake. The one human study's authors list a senescence-treatment patent application and Iota Biosciences royalties. Some mouse-study authors hold Mayo Clinic senolytic patents. This adds to the very low confidence.

• Company stake 1
• No disclosure in PubMed 1
• No stake declared 1

• Hambright 2024Company stake
• Yamaura 2022No disclosure in PubMed
• Gruendler 2020No stake declared

Funding rule. A stake is always shown. Confidence is lowered only when every supporting study comes from a party with a stake. "No disclosure in PubMed" means the PubMed record has no conflict-of-interest statement. It does not mean there is no conflict.

All 12 on-topic papers

Each paper shows what it tested, what it found, and who has a stake. Every paper also has its own page that explains how much it counts and how it fits. See every study as a list.

1. Population study: one-time surveyHambright et al., 2024Aging cell · PubMed

   Clinical validation of C12FDG as a marker associated with senescence and osteoarthritic phenotypes.

   healthy adults and adults with osteoarthritis; a small subgroup took fisetin

   TestedBlood test for worn-out cells measured in a large group; a few people were taking fisetin

   Worn-out blood cells rose with age and in osteoarthritis. The share of these cells and age-linked blood markers were lower in a small subgroup taking fisetin. The abstract gives no group size.

   Points to benefitCompany stakeAbstract only

   Several authors list a patent application on treating senescence-linked disease; one reports royalties from Iota Biosciences.

   Read the study page

2. Animal studySuda et al., 2025Cell metabolism · PubMed

   Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice.

   obese mice

   TestedGene-based removal of worn-out blood-vessel cells; fisetin given to obese mice

   Removing worn-out blood-vessel cells eased metabolic problems in obese mice. Fisetin reduced these cells in fat tissue and improved glucose handling.

   Points to benefitCompany stakeAbstract only

   Several authors hold patents on senolytic drugs through Mayo Clinic.

   Read the study page

3. Animal studyRodriguez Morales et al., 2025Circulation research · PubMed

   Vascular Niches Are the Primary Hotspots in Cardiac Aging.

   young (3-month) and old (18-month) mice

   TestedOld mice given dasatinib plus quercetin, or fisetin, to clear worn-out cells

   Old hearts had worn-out cells clustered around blood vessels. Clearing them with senolytics lowered one type of immune cell (Lyve1- macrophages). Fisetin effect is not given separately.

   Points to benefitNo stake declaredAbstract only

   COI statement says none.

   Read the study page

4. Animal studyLi et al., 2023JCI insight · PubMed

   Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity.

   mice with kidney damage from the cancer drug cisplatin

   TestedTwo senolytic drugs, ABT-263 and fisetin, given to mice after cisplatin

   Clearing worn-out kidney cells with ABT-263 and fisetin reduced scarring and improved kidney repair and function in mice. Abstract gives no numbers.

   Points to benefitNo stake declaredAbstract only

   No conflict of interest exists, per the authors.

   Read the study page

5. Animal studyLiu et al., 2022Aging · PubMed

   Senolytic elimination of senescent macrophages restores muscle stem cell function in severely dystrophic muscle.

   mice with severe muscular dystrophy

   TestedFisetin given to mice for 4 weeks

   Fisetin reduced worn-out immune cells, restored muscle cell numbers and improved muscle traits in dystrophic mice after 4 weeks.

   Points to benefitNo stake declaredAbstract only

   The authors declare no conflicts of interest.

   Read the study page

6. Animal studySaito et al., 2021Frontiers in immunology · PubMed

   Accumulation of Senescent Neural Cells in Murine Lupus With Depression-Like Behavior.

   lupus-prone mice with depression-like behavior

   TestedFisetin by mouth to mice with lupus

   Fisetin lowered the number of worn-out brain cells and reduced depression-like behavior in lupus mice. Worn-out cell gene signals in the hippocampus also fell.

   Points to benefitNo stake declaredAbstract only

   No competing interests declared.

   Read the study page

7. Cell studyAnnunziata et al., 2023Cell stress · PubMed

   A versatile method for the identification of senolytic compounds.

   mouse and human cells in dishes

   TestedNew lab screening method; fisetin tested on worn-out cells

   Fisetin killed worn-out mouse embryo cells but not worn-out human melanoma cells in the new test.

   MixedCompany stakeAbstract only

   One author consulted for Ono Pharmaceutical Co., Ltd.; the record does not say what it sells.

   Read the study page

8. Systematic reviewYamaura et al., 2022Pharmacological research · PubMed

   The effects of fisetin on bone and cartilage: A systematic review.

   13 studies · lab cell and animal models of bone loss and joint wear (osteoporosis, osteoarthritis)

   TestedFisetin given to cells and animals, compared with no fisetin, across 13 studies

   Across 13 cell and animal studies, fisetin had good effects on bone loss and, in fewer reports, on joint wear. No human data. Studies differed too much to pool.

   Points to benefitNo disclosure in PubMedAbstract only

   No disclosure in PubMed.

   Read the study page

9. Systematic reviewGruendler et al., 2020Molecules (Basel, Switzerland) · PubMed

   Nutraceutical Approaches of Autophagy and Neuroinflammation in Alzheimer's Disease: A Systematic Review.

   studies on Alzheimer's disease; the abstract does not say if in people, animals or cells

   TestedReview of three food-derived substances, including fisetin, and their effect on cell clean-up, brain inflammation and cell aging

   The authors say the reviewed substances, fisetin among them, looked helpful on cell clean-up, brain inflammation and cell aging. The abstract gives no numbers and no fisetin-only results.

   Points to benefitNo stake declaredAbstract only

   The authors declare no conflict of interest.

   Read the study page

10. OtherTang et al., 2026Current pharmaceutical design · PubMed

    Jiawei Zaoqi Decoction Attenuates Polycystic Ovary Syndrome by Inhibiting AGE-RAGE-Mediated Cell Senescence of Granulosa Cells.

    women and rats with polycystic ovary syndrome; ovary cells in dishes

    TestedA Chinese herbal mix was tested; fisetin and quercetin were tested alone on ovary cells

    The herbal mix lowered hormone levels in patients and rats. In dishes, fisetin and quercetin lowered cell-aging markers in ovary cells.

    No weight on the ladderNo disclosure in PubMedAbstract only

    No disclosure in PubMed.

    Read the study page

11. Opinion or narrative reviewRzeski et al., 2026Nutrients · PubMed

    Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A.

    people and lab models, in a review of four natural compounds

    TestedReview of four compounds, including fisetin, and how they act on aging pathways

    Narrative review says fisetin clears worn-out cells in lab work and has emerging clinical evidence. It gives no trial numbers.

    No weight on the ladderNo stake declaredAbstract only

    The authors declare no conflicts of interest.

    Read the study page

12. Opinion or narrative reviewWang et al., 2021Journal of agricultural and food chemistry · PubMed

    Prospective Selective Mechanism of Emerging Senolytic Agents Derived from Flavonoids.

    no people or animals tested

    TestedProposed explanation of how fisetin and quercetin kill worn-out cells

    Authors propose that fisetin and quercetin kill worn-out cells by oxidative damage helped by copper and iron. No new data on aging outcomes.

    No weight on the ladderNo disclosure in PubMedAbstract only

    No disclosure in PubMed.

    Read the study page

Words on this page

Marker

A lab or scan result that stands in for a health outcome. A better marker does not always mean better health.

How the short answer is set

Fixed rules turn the studies into the short answer, so the same studies always give the same answer. The rules start from GRADE, a standard system for rating evidence, in plain language.

Why very low here

• No trial in people tested fisetin on aging, frailty, disease or lifespan.
• Only human data: one small subgroup in one study, with no numbers given.
• That study measured blood markers only; several authors hold a senescence-treatment patent application.
• Animal studies mostly used disease models, such as obesity or kidney damage, not natural aging.

Hard limit used. With no human trial of fisetin measuring aging, frailty, age-related disease or lifespan, the answer cannot say it works in people.

How this page was made

Search. We ran four PubMed searches for fisetin and aging and senescent cells: pooled and systematic reviews since 2012 (3 of 3), trials in people (1 of 1), population studies (5 of 5), animal studies (6 of 55). The first number is how many papers we read; the second is how many PubMed found. We took the ones PubMed ranks as most relevant. See the full PubMed search. Of the 15 papers read, 12 were on topic.

Limits. Digestery reads at most about 60 papers per question, so large fields are sampled, not covered in full. Abstracts can leave out key details, such as side effects and funding.

Review queue

These items wait for a person. Search engines are asked not to list the page until the first one is done.

1. OpenThe short answer is new. It waits for a source check by a person.
2. OpenPubMed tags Chen 2021 as a clinical trial, but fisetin was tested only in lung cancer cells; marked off-topic. Confirm no human fisetin trial was missed.
3. OpenHambright 2024: fisetin subgroup size, dose and comparison are not in the abstract; check the full text before stating any human effect.
4. OpenGlossmann 2019 mentions a frailty trial of an unnamed plant-derived senolytic; check whether it is a fisetin trial that belongs in watch.
5. OpenAnnunziata 2023: author consulted for Ono Pharmaceutical; coded as company stake, but check whether Ono makes or sells senolytics.
6. OpenSuda 2025: senolytic patents are held by Mayo Clinic, not a company; coded as company stake. Confirm this coding rule.
7. OpenWang 2021 and Tang 2026 set relevant on borderline grounds: a mechanism perspective, and a cell-dish side test inside an herbal formula study.
8. OpenPack has only 15 papers and no protocols; consider a wider search for human fisetin studies and registered trials.

Page history

Flag an error

A flag must point to a source: the passage in the paper, or a link to a study this page missed. A flag starts a new check. Votes never change a page.